Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/=18 years of age
Diagnosis of diabetes mellitus type 2
Patients treated with stable metformin monotherapy for at least 12 weeks prior to screening
HbA1c \>/=7% and \</=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit
Fasting plasma glucose \</=240 mg/dL at pre-randomization visit
Agreement to maintain diet and exercise habits during the study
You may not be if
Patients with Type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months
Any previous treatment with thiazolidinedione or a dual PPAR agonist
Any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin)
Symptomatic congestive heart failure classified as New York Heart Association class II-IV at screening
Clareo Health | A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone
